期刊
JOURNAL OF INFECTIOUS DISEASES
卷 222, 期 5, 页码 722-725出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiaa350
关键词
SARS-CoV-2; IFN-beta-1a; COVID-19 clinical trial
The ongoing coronavirus disease 2019 pandemic has forced the clinical and scientific community to try drug repurposing of existing antiviral agents as a quick option against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Under this scenario, interferon (IFN) beta-1a, whose antiviral potential is already known, and which is a drug currently used in the clinical management of multiple sclerosis, may represent as a potential candidate. In this report, we demonstrate that IFN-beta-1a was highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically achievable concentration when administered after virus infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据